1374962-72-7

Basic information

• Product Name: 2-BENZENESULFONYLAMINO-4-METHYL-PENTANOIC ACID
• Synonyms: 2-BENZENESULFONYLAMINO-4-METHYL-PENTANOIC ACID;2-benzenesulfonamido-4-methylpentanoic acid
• CAS NO: 1374962-72-7
• Molecular Formula: C12H17NO4S
• Molecular Weight: 271.33
• Mol File: 1374962-72-7.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-BENZENESULFONYLAMINO-4-METHYL-PENTANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BENZENESULFONYLAMINO-4-METHYL-PENTANOIC ACID(1374962-72-7)
• EPA Substance Registry System: 2-BENZENESULFONYLAMINO-4-METHYL-PENTANOIC ACID(1374962-72-7)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 1374962-72-7(Hazardous Substances Data)

Upstream product

• 328-38-1 (R)-leucine 
• 98-09-9 benzenesulfonyl chloride 
• 1738-77-8 L-leucine benzyl ester p-toluenesulfonate 
• 61-90-5 L-leucine 
• 2666-93-5 (S)-Leu-OMe 
• 68305-82-8 methyl (S)-4-methyl-2-(phenylsulfonamido)pentanoate 
• 328-39-2 LEUCINE 
• 1939-99-7 benzenesulfonyl chloride 
• 2743-40-0 L-leucine ethyl ester hydrochloride 
• 1370706-01-6 (S)-ethyl 4-methyl-2-(phenylsulfonamido)pentanoate 

Downstream Products

• 1374962-73-8 N-benzenesulfonyl-D,L-leucyl-L-proline benzyl ester 
• 1374962-74-9 N-benzenesulfonyl-D,L-leucyl-L-proline 
• 1374962-75-0 N-benzenesulfonyl-D,L-leucyl-L-proline-[(4-cyanophenyl)methyl]amide 
• 1374962-07-8 C₂₅H₃₃N₅O₅S 
• 1374962-09-0 N-benzenesulfonyl-D,L-leucyl-L-prolyl-[(4-amidinophenyl)methyl]amide acetate 
• 1370705-88-6 (R)-4-methyl-N-((4-phenyl-1,2,5-oxadiazol-3-yl)methyl)-2-(phenylsulfonamido)pentanamide 
• 1374963-17-3 N-benzenesulfonyl-D-leucyl-L-homoproline 
• 1374962-30-7 N-benzenesulfonyl-D-leucyl-L-prolyl-{[4-(N-benzyloxycarbonyl)amidinophenyl]methyl} amide 
• 1374963-38-8 C₂₃H₂₈N₄O₄S₂ 
• 1374963-16-2 N-benzenesulfonyl-D-leucyl-L-homoproline benzyl ester 
• 1374962-63-6 C₃₁H₄₃N₅O₆S 
• 1374962-62-5 C₃₁H₄₃N₅O₅S 
• 1374962-60-3 C₂₄H₃₈N₄O₄S*ClH 

Relevant articles and documents

Synthesis and Structure-Activity Relationships of Arylsulfonamides as AIMP2-DX2 Inhibitors for the Development of a Novel Anticancer Therapy

AIMP2-DX2, a splicing variant of AIMP2, is up-regulated in lung cancer, possesses oncogenic activity, and results in tumorigenesis. Specifically inhibiting the interaction between AIMP2-DX2 and HSP70 to suppress AIMP2-DX2-dependent cancers with small molecules is considered a promising avenue for cancer therapeutics. Optimization of hit BC-DXI-04 (IC50 = 40.1 μM) provided new potent sulfonamide based AIMP2-DX2 inhibitors. Among these, BC-DXI-843 showed improved inhibition against AIMP2-DX2 (IC50 = 0.92 μM) with more than 100-fold selectivity over AIMP2 in a luciferase assay. Several binding assays indicated that this compound effectively induces cancer cell apoptosis by specifically interrupting the interaction between DX2 and HSP70, which leads to the degradation of DX2 via Siah1-mediated ubiquitination. More importantly, BC-DXI-843 demonstrated in vivo efficacy in a tumor xenograft mouse model (H460 cells) at a dosage of 50 mg/kg, suggesting it as a promising lead for development of novel therapeutics targeting AIMP2-DX2 in lung cancer.

New carboxamides bearing benzenesulphonamides: Synthesis, molecular docking and pharmacological properties

Ten new derivatives of benzenesulphonamide bearing carboxamide functionality were synthesized and investigated for their in vitro antimicrobial, antioxidant and in vivo anti-inflammatory activities. Compound 9d inhibited carrageenan induced rat-paw oedema

Synthesis, characterization and in vitro antitrypanosomal activities of new carboxamides bearing quinoline moiety

The reported toxicities of current antitrypanosomal drugs and the emergence of drug resistant trypanosomes underscore the need for the development of new antitrypanosomal agents. We report herein the synthesis and antitrypanosomal activity of 24 new amide derivatives of 3-aminoquinoline, bearing substituted benzenesulphonamide. Nine of the new derivatives showed comparable antitrypanosomal activities at IC50 range of 1–6 nM (melarsoprol 5 nM). Compound 11n and 11v are more promising antitrypanosomal agents with IC50 1.0 nM than the rest of the reported derivatives. The novel compounds showed satisfactory predicted physico-chemical properties including oral bioavailability, permeability and transport properties.